USA flag logo/image

An Official Website of the United States Government

DIRECT RADIOMETAL LABELING FOR IMAGING AND THERAPY

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
19018
Program Year/Program:
1992 / SBIR
Agency Tracking Number:
19018
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Rhomed, Inc.
C/O PALATIN TECHNOLOGIES, INC. Princeton, NJ 08540
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1992
Title: DIRECT RADIOMETAL LABELING FOR IMAGING AND THERAPY
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

ANTIBODIES OR ANTIBODY FRAGMENTS, REDUCED AND LYOPHILIZED FOR USE IN PREPARING INSTANT, ONE-STEP TC-99M RADIOPHARMACEUTICALS, CAN ALSO BE LABELED WITH CU-67. THE CU-67, AS CU(II) IN A PH 5.6 BUFFER, IS SIMPLY ADDED TO THE ANTIBODY TO GENERATE THE CU-67-LABELED ANTIBODY. THE PURPOSE OF THIS PROJECT IS TO DETERMINE THE PARAMETERS OF THIS REACTION AND THE PURITY, STABILITY, AND IMMUNO-REACTIVITY OF THE RESULTANT RADIOLABELED PRODUCT. DURING PHASE II, DIRECT LABELING USING CU-67 AND OTHER RADIOMETALS WILL BE EVALUATED AND THE PRODUCTS WILL BE TESTED IN ANIMAL MODELS COMPARED TO THE SAME ANTIBODY LABELED WITH TC-99M. ULTIMATELY, RADIOLABELED ANTIBODIES WILL BE MADE FOR THERAPY AND PET IMAGING STUDIES. THIS APPROACH PERMITS THE SAME ANTIBODY, USING THE SAME LABELING CHEMISTRY, TO BE LABELED WITH SEVERAL DIFFERENT RADIO METALS, INCLUDING TC-99M AND CU-67. PHASE III STUDIES WILL INCLUDE HUMAN TRIALS OF VALIDATED AND CLINICALLY RELEVANT DIAGNOSTIC OR THERAPEUTIC RADIOPHARMACEUTICALS.

Principal Investigator:

Paul O Zamora
5053447200

Business Contact:

Small Business Information at Submission:

Rhomed Inc
4216 Balloon Park Road Ne Albuquerque, NM 87109

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No